Novel approaches to the control of graft versus host disease.
Graft versus host disease (GVHD) remains the major obstacle to the application of bone marrow transplantation across HLA barriers. Recent advances in our understanding of GVHD pathophysiology have resulted in the evaluation in animal models and in clinical trials of some novel approaches to avoiding and treating GVHD. Continued advances in our knowledge are likely to result in the clinical application of biological therapies to maximize graft versus leukemia effects and alloengraftment, while avoiding GVHD.
Sykes
M
M
Harvard Medical School, Boston.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001803:Blood Transfusion; D001853:Bone Marrow / Q000528:radiation effects; D016026:Bone Marrow Transplantation / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control*; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents; D009569:Nitric Oxide / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous / Q000276:immunology
D000911:Antibodies, Monoclonal; D016207:Cytokines; D007166:Immunosuppressive Agents; D009569:Nitric Oxide